

Press Release

## Granules India appoints Dr. Saumen Chakraborty as Non-executive Independent Director

**Hyderabad, 14<sup>th</sup> Dec, 2021:** Granules India Limited, a vertically integrated pharmaceutical company, today announced the appointment of Dr. Saumen Chakraborty as Non-executive Independent Director on the Board of the Company with immediate effect. Dr. Chakraborty retired as the President and Chief Financial Officer of Dr. Reddy's in November 2020 and continued to advise the company for the next one year.

Commenting on the appointment, **Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited** said, *"We are delighted to have Dr. Chakraborty on the board of our company. His remarkable experience in the pharmaceuticals industry on the global platform will be of great value for us. I am confident that he will guide the company to newer heights in line with our long-term goals."*

With over 37 years of experience in the field of strategic and operational aspects of management, Dr. Saumen Chakraborty has played significant role in the evolution of Dr. Reddy's as a global pharmaceutical company from India. Prior to Dr. Reddy's, he worked at CMC, C-DOT, Eicher and Tecumseh.

Dr. Chakraborty is a Postgraduate in Management from IIM-Ahmedabad and an executive fellow in Management from the Indian School of Business, Hyderabad.

### About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

### Media Contact:

<b>Karthik Chittoor</b>	<b>Naresh Gaddam</b>
Corporate Communications	Fortuna PR
Email: <a href="mailto:Karthik.chittoor@granulesindia.com">Karthik.chittoor@granulesindia.com</a>	Email: <a href="mailto:naresh@fortunapr.com">naresh@fortunapr.com</a>
Mob: 90300 88669	Mob: 98483 35510